{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:56:46Z","timestamp":1790146606322,"version":"4.0.1"},"reference-count":142,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T00:00:00Z","timestamp":1581984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.00188","type":"journal-article","created":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T04:54:44Z","timestamp":1582001684000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":141,"title":["The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease"],"prefix":"10.3389","volume":"11","author":[{"given":"Anna Rosa","family":"Garbuglia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Lapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catia","family":"Sias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosaria","family":"Capobianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Del Porto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,2,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/ijc.31937","article-title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods","volume":"144","author":"Ferlay","year":"2019","journal-title":"Int J Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e609","DOI":"10.1016\/S2214-109X(16)30143-7","article-title":"Global burden of cancers attributable to infections in 2012: a synthetic analysis","volume":"4","author":"Plummer","year":"2016","journal-title":"Lancet Glob Health"},{"key":"B3","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S0140-6736(13)60022-7","article-title":"Human papillomavirus and cervical cancer","volume":"382","author":"Crosbie","year":"2013","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/bjc.2014.362","article-title":"50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence","volume":"111","author":"Vaccarella","year":"2014","journal-title":"Br J Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"S3\/42","DOI":"10.1016\/j.vaccine.2006.06.018","article-title":"Chapter 5: updating the natural history of HPV and anogenital cancer","volume":"24","author":"Moscicki","year":"2006","journal-title":"Vaccine"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1086\/315498","article-title":"Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection","volume":"181","author":"Carter","year":"2000","journal-title":"J Infect Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"719","DOI":"10.2471\/BLT.06.038414","article-title":"Human papillomavirus and HPV vaccines: a review","volume":"85","author":"Cutts","year":"2007","journal-title":"Bull World Health Organ"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1002\/ijc.27485","article-title":"Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer","volume":"131","author":"Guan","year":"2012","journal-title":"Int J Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/978-1-4612-2042-8","article-title":"Second edition of \u2018wfhe Bethesda System for reporting cervical cytology\u2019 - atlas, website, and Bethesda interobserver reproducibility project","volume":"1","author":"Nayar","year":"2004","journal-title":"Cytojournal."},{"key":"B10","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ijc.30716","article-title":"Worldwide burden of cancer attributable to HPV by site, country and HPV type","volume":"141","author":"de Martel","year":"2017","journal-title":"Int J Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/cncr.20365","article-title":"Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer","volume":"101","author":"Daling","year":"2004","journal-title":"Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1473-3099(17)30653-9","article-title":"Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis","volume":"18","author":"Lin","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/S1473-3099(19)30164-1","article-title":"Cervical determinants of anal HPV infection and high-grade anal lesions in women: a collaborative pooled analysis","volume":"19","author":"Lin","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jcv.2015.09.001","article-title":"An anal cancer screening program for MSM in Italy: prevalence of multiple HPV types and vaccine-targeted infections","volume":"72","author":"Garbuglia","year":"2015","journal-title":"J Clin Virol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1086\/507432","article-title":"Prevalence of HPV infection among men: a systematic review of the literature","volume":"194","author":"Dunne","year":"2006","journal-title":"J Infect Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1158\/1055-9965.EPI-06-0997","article-title":"Human papillomavirus prevalence and type distribution in male anogenital sites and semen","volume":"16","author":"Nielson","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1086\/521632","article-title":"Risk factors for anogenital human papillomavirus infection in men","volume":"196","author":"Nielson","year":"2007","journal-title":"J Infect Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"K17","DOI":"10.1016\/j.vaccine.2008.06.021","article-title":"Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions","volume":"26","author":"Giuliano","year":"2008","journal-title":"Vaccine"},{"key":"B19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.bpobgyn.2005.10.007","article-title":"Worldwide burden of gynaecological cancer: the size of the problem","volume":"20","author":"Sankaranarayanan","year":"2006","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.1016\/j.ejca.2013.06.033","article-title":"Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva","volume":"49","author":"de","year":"2013","journal-title":"Eur J Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.pathol.2016.02.015","article-title":"Squamous precursor lesions of the vulva: current classification and diagnostic challenges","volume":"48","author":"Hoang","year":"2016","journal-title":"Pathology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/LGT.0000000000000169","article-title":"The 2015 International society for the study of vulvovaginal disease (ISSVD) terminology of vulvar squamous intraepithelial lesions","volume":"20","author":"Bornstein","year":"2016","journal-title":"J Low Genit Tract Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/01.pgp.0000177646.38266.6a","article-title":"Vulvar squamous cell carcinoma is a multifactorial disease following two separate and independent pathways","volume":"25","author":"van der Avoort","year":"2006","journal-title":"Int J Gynecol Pathol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1097\/01.pas.0000213291.96401.48","article-title":"The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN)","volume":"30","author":"Srodon","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1055\/s-0035-1558052","article-title":"Precancerous lesions of the cervix, vulva and vagina according to the 2014 WHO classification of tumors of the female genital tract","volume":"75","author":"Reich","year":"2015","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"B26","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S0029-7844(97)00467-5","article-title":"Human papillomavirus type 16 and risk of preinvasive and invasive vulvar cancer: results from a seroepidemiological case-control study","volume":"90","author":"Hildesheim","year":"1997","journal-title":"Obstet Gynecol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1006\/gyno.2001.6502","article-title":"A population-based study of squamous cell vaginal cancer: HPV and cofactors","volume":"84","author":"Daling","year":"2002","journal-title":"Gynecol Oncol"},{"key":"B28","first-page":"1934","article-title":"Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites","volume":"61","author":"Carter","year":"2001","journal-title":"Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e0167386","DOI":"10.1371\/journal.pone.0167386","article-title":"Detection of human papillomavirus infection in patients with vaginal intraepithelial neoplasia","volume":"11","author":"Lamos","year":"2016","journal-title":"PLoS ONE"},{"key":"B30","doi-asserted-by":"publisher","first-page":"S3\/11","DOI":"10.1016\/j.vaccine.2006.05.111","article-title":"Chapter 2: The burden of HPV-related cancers","volume":"24","author":"Parkin","year":"2006","journal-title":"Vaccine"},{"key":"B31","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1158\/1055-9965.EPI-04-0551","article-title":"Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review","volume":"14","author":"Kreimer","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B32","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.oraloncology.2007.02.005","article-title":"Human papillomavirus infection and oral cancer: a case-control study in Montreal, Canada","volume":"44","author":"Pintos","year":"2008","journal-title":"Oral Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"H1","DOI":"10.1016\/j.vaccine.2013.07.026","article-title":"Comprehensive control of human papillomavirus infections and related diseases","volume":"31","author":"Bosch","year":"2013","journal-title":"Vaccine"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e68329","DOI":"10.1371\/journal.pone.0068329","article-title":"Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica","volume":"8","author":"Herrero","year":"2013","journal-title":"PLoS ONE"},{"key":"B35","doi-asserted-by":"publisher","first-page":"djv344","DOI":"10.1093\/jnci\/djv344","article-title":"HPV-associated head and neck cancer","volume":"107","author":"Vokes","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"B36","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1158\/1940-6207.CAPR-15-0101","article-title":"The impact of tonsillectomy upon the risk of oropharyngeal carcinoma diagnosis and prognosis in the danish cancer registry","volume":"8","author":"Fakhry","year":"2015","journal-title":"Cancer Prev Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1038\/ng.3685","article-title":"Genome-wide association analyses identify new susceptibility loci for oral cavity and pharyngeal cancer","volume":"48","author":"Lesseur","year":"2016","journal-title":"Nat Genet"},{"key":"B38","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3109\/00016488809097020","article-title":"Juvenile laryngeal papillomatosis. an epidemiological study from the Copenhagen region","volume":"105","author":"Bomholt","year":"1988","journal-title":"Acta Otolaryngol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/path.1711650308","article-title":"Human papillomavirus 6, 11, and 16 in laryngeal papillomas","volume":"165","author":"Dickens","year":"1991","journal-title":"J Pathol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/000348940611500101","article-title":"Recurrent respiratory papillomatosis","volume":"115","author":"Derkay","year":"2006","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/S0140-6736(01)06886-6","article-title":"Sexual behaviour in Britain: reported sexually transmitted infections and prevalent genital Chlamydia trachomatis infection","volume":"358","author":"Fenton","year":"2001","journal-title":"Lancet"},{"key":"B42","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/j.1467-842X.2003.tb00813.x","article-title":"Sex in Australia: knowledge about sexually transmissible infections and blood-borne viruses in a representative sample of adults","volume":"27","author":"Grulich","year":"2003","journal-title":"Aust N Z J Public Health"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1086\/522863","article-title":"The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries","volume":"196","author":"Kjaer","year":"2007","journal-title":"J Infect Dis"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1086\/375074","article-title":"The health and economic burden of genital warts in a set of private health plans in the United States","volume":"36","author":"Insinga","year":"2003","journal-title":"Clin Infect Dis"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.2165\/00019053-200523110-00004","article-title":"Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature","volume":"23","author":"Insinga","year":"2005","journal-title":"Pharmacoeconomics."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1111\/j.1440-1746.2012.07204.x","article-title":"Gastrointestinal: anal buschke loewenstein tumor","volume":"27","author":"Albuquerque","year":"2012","journal-title":"J Gastroenterol Hepatol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"8166","DOI":"10.1128\/JVI.72.10.8166-8173.1998","article-title":"A fifteen-amino-acid peptide inhibits human papillomavirus E1-E2 interaction and human papillomavirus DNA replication in vitro","volume":"72","author":"Kasukawa","year":"1998","journal-title":"J Virol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/ijc.2910430422","article-title":"Properties of a non-tumorigenic human cervical keratinocyte cell line","volume":"43","author":"Stanley","year":"1989","journal-title":"Int J Cancer"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1128\/JVI.65.5.2254-2260.1991","article-title":"Amplification of human papillomavirus genomes in vitro is dependent on epithelial differentiation","volume":"65","author":"Bedell","year":"1991","journal-title":"J Virol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.molcel.2006.11.005","article-title":"ChlR1 is required for loading papillomavirus E2 onto mitotic chromosomes and viral genome maintenance","volume":"24","author":"Parish","year":"2006","journal-title":"Mol Cell"},{"key":"B51","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0065-3527(08)00404-1","article-title":"Replication and partitioning of papillomavirus genomes","volume":"72","author":"McBride","year":"2008","journal-title":"Adv Virus Res"},{"key":"B52","doi-asserted-by":"publisher","first-page":"4030","DOI":"10.1073\/pnas.0306848101","article-title":"Human papillomavirus (HPV) origin-binding protein associates with mitotic spindles to enable viral DNA partitioning","volume":"101","author":"Van Tine","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"B53","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.virol.2013.07.020","article-title":"The E1 proteins","volume":"445","author":"Bergvall","year":"2013","journal-title":"Virology."},{"key":"B54","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/path.4496","article-title":"Pathogenesis of human papillomavirus-associated mucosal disease","volume":"235","author":"Groves","year":"2015","journal-title":"J Pathol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"8909","DOI":"10.1128\/JVI.00502-06","article-title":"Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen interacts with bromodomain protein Brd4 on host mitotic chromosomes","volume":"80","author":"You","year":"2006","journal-title":"J Virol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e1006282","DOI":"10.1371\/journal.ppat.1006282","article-title":"HPV16 and 18 genome amplification show different E4-dependence, with 16E4 enhancing E1 nuclear accumulation and replicative efficiency via its cell cycle arrest and kinase activation functions","volume":"13","author":"Egawa","year":"2017","journal-title":"PLoS Pathog"},{"key":"B57","doi-asserted-by":"publisher","first-page":"11677","DOI":"10.1128\/JVI.79.18.11677-11684.2005","article-title":"Combined effect of CCR5-Delta32 heterozygosity and the CCR5 promoter polymorphism\u22122459 A\/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmission","volume":"79","author":"Hladik","year":"2005","journal-title":"J Virol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3390\/v10010037","article-title":"Structural insights in multifunctional papillomavirus oncoproteins","volume":"10","author":"Suarez","year":"2018","journal-title":"Viruses"},{"key":"B59","doi-asserted-by":"publisher","first-page":"9737","DOI":"10.1128\/JVI.00881-07","article-title":"Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor","volume":"81","author":"Huh","year":"2007","journal-title":"J Virol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1073\/pnas.0510012103","article-title":"The E7 proteins of low- and high-risk human papillomaviruses share the ability to target the pRB family member p130 for degradation","volume":"103","author":"Zhang","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"B61","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nrc2886","article-title":"Human papillomavirus oncoproteins: pathways to transformation","volume":"10","author":"Moody","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.virol.2013.04.035","article-title":"Regulatory elements in the viral genome","volume":"445","author":"Bernard","year":"2013","journal-title":"Virology"},{"key":"B63","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.virol.2013.04.034","article-title":"Papillomavirus transcripts and post-transcriptional regulation","volume":"445","author":"Schwartz","year":"2013","journal-title":"Virology"},{"key":"B64","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nrmicro2984","article-title":"Regulation of human papillomavirus gene expression by splicing and polyadenylation","volume":"11","author":"Johansson","year":"2013","journal-title":"Nat Rev Microbiol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"F55","DOI":"10.1016\/0304-419X(96)00020-0","article-title":"Papillomavirus infections\u2013a major cause of human cancers","volume":"1288","author":"zur Hausen","year":"1996","journal-title":"Biochim Biophys Acta"},{"key":"B66","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/path.2192","article-title":"Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis?","volume":"212","author":"Pett","year":"2007","journal-title":"J Pathol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.ygyno.2008.02.003","article-title":"Immunobiology of HPV and HPV vaccines","volume":"109","author":"Stanley","year":"2008","journal-title":"Gynecol Oncol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1086\/317638","article-title":"A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types","volume":"183","author":"Liaw","year":"2001","journal-title":"J Infect Dis"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1016\/S0140-6736(00)04956-4","article-title":"Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study","volume":"357","author":"Woodman","year":"2001","journal-title":"Lancet"},{"key":"B70","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0168-1702(02)00196-X","article-title":"The status of HPV16-specific T-cell reactivity in health and disease as a guide to HPV vaccine development","volume":"89","author":"van der Burg","year":"2002","journal-title":"Virus Res"},{"key":"B71","doi-asserted-by":"publisher","first-page":"5449","DOI":"10.1158\/0008-5472.CAN-04-0831","article-title":"Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6","volume":"64","author":"de Jong","year":"2004","journal-title":"Cancer Res"},{"key":"B72","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/ijc.21394","article-title":"Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia","volume":"118","author":"van Poelgeest","year":"2006","journal-title":"Int J Cancer"},{"key":"B73","doi-asserted-by":"publisher","first-page":"5273","DOI":"10.1158\/1078-0432.CCR-05-0616","article-title":"Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment","volume":"11","author":"van Poelgeest","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B74","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/ijc.21459","article-title":"Detection of human papillomavirus type 18 E6 and E7-specific CD4+ T-helper 1 immunity in relation to health versus disease","volume":"118","author":"Welters","year":"2006","journal-title":"Int J Cancer"},{"key":"B75","doi-asserted-by":"publisher","first-page":"854237","DOI":"10.5402\/2012\/854237","article-title":"CD8 T-cell responses in incident and prevalent human papillomavirus types 16 and 18 infections","volume":"2012","author":"Coleman","year":"2012","journal-title":"ISRN Obstet Gynecol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1158\/0008-5472.CAN-06-3388","article-title":"High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer","volume":"67","author":"Piersma","year":"2007","journal-title":"Cancer Res"},{"key":"B77","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1093\/infdis\/174.5.927","article-title":"The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women","volume":"174","author":"Carter","year":"1996","journal-title":"J Infect Dis"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1002\/jmv.23664","article-title":"Association of HPV types 6, 11, 16, and 18 DNA detection and serological response in unvaccinated adolescent women","volume":"85","author":"Tong","year":"2013","journal-title":"J Med Virol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/OLQ.0000000000000236","article-title":"A longitudinal study of human papillomavirus 16 L1, e6, and e7 seropositivity and oral human papillomavirus 16 infection","volume":"42","author":"Beachler","year":"2015","journal-title":"Sex Transm Dis"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1093\/jnci\/djq384","article-title":"Epidemiological study of anti-HPV16\/18 seropositivity and subsequent risk of HPV16 and\u221218 infections","volume":"102","author":"Safaeian","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"B81","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1093\/infdis\/jiu143","article-title":"Naturally acquired immunity against human papillomavirus (HPV): why it matters in the HPV vaccine era","volume":"210","author":"Franceschi","year":"2014","journal-title":"J Infect Dis"},{"key":"B82","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/infdis\/jiu139","article-title":"Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16\/18 antibodies: analysis of the control arm of PATRICIA","volume":"210","author":"Castellsagu\u00e9","year":"2014","journal-title":"J Infect Dis"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1093\/infdis\/jiv753","article-title":"Natural acquired immunity against subsequent genital human papillomavirus infection: a systematic review and meta-analysis","volume":"213","author":"Beachler","year":"2016","journal-title":"J Infect Dis"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1001\/jama.2013.1625","article-title":"Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial","volume":"309","author":"Dobson","year":"2013","journal-title":"JAMA"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.15585\/mmwr.mm6549a5","article-title":"Use of a 2-dose schedule for human papillomavirus vaccination - updated recommendations of the advisory committee on immunization practices","volume":"65","author":"Meites","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B86","first-page":"1","article-title":"Human papillomavirus vaccination: recommendations of the advisory committee on immunization practices (ACIP)","volume":"63","author":"Markowitz","year":"2014","journal-title":"MMWR Recomm Rep"},{"key":"B87","doi-asserted-by":"publisher","first-page":"F83","DOI":"10.1016\/j.vaccine.2012.04.106","article-title":"Human papillomavirus vaccines\u2014immune responses","volume":"30","author":"Stanley","year":"2012","journal-title":"Vaccine"},{"key":"B88","doi-asserted-by":"publisher","first-page":"11553","DOI":"10.1073\/pnas.92.25.11553","article-title":"Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas","volume":"92","author":"Suzich","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"B89","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.1128\/JVI.69.8.5147-5151.1995","article-title":"Papillomavirus L1 capsids agglutinate mouse erythrocytes through a proteinaceous receptor","volume":"69","author":"Roden","year":"1995","journal-title":"J Virol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/S0140-6736(09)61567-1","article-title":"Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6","volume":"374","author":"Romanowski","year":"2009","journal-title":"Lancet"},{"key":"B91","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1002\/cam4.1155","article-title":"Ten-year immune persistence and safety of the HPV-16\/18 AS04-adjuvanted vaccine in females vaccinated at 15-55 years of age","volume":"6","author":"Schwarz","year":"2017","journal-title":"Cancer Med"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"key":"B93","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.jadohealth.2007.02.015","article-title":"Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant","volume":"40","author":"Pedersen","year":"2007","journal-title":"J Adolesc Health"},{"key":"B94","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N Engl J Med"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1080\/14760584.2018.1548282","article-title":"Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials","volume":"17","author":"Arbyn","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"B96","doi-asserted-by":"publisher","first-page":"5087","DOI":"10.1016\/j.vaccine.2014.06.038","article-title":"Efficacy of the HPV-16\/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16\/18 vaccine trial","volume":"32","author":"Hildesheim","year":"2014","journal-title":"Vaccine"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1056\/NEJMoa1010971","article-title":"HPV vaccine against anal HPV infection and anal intraepithelial neoplasia","volume":"365","author":"Palefsky","year":"2011","journal-title":"N Engl J Med."},{"key":"B98","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1056\/NEJMoa0909537","article-title":"Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males","volume":"364","author":"Giuliano","year":"2011","journal-title":"N Engl J Med"},{"key":"B99","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/infdis\/jix415","article-title":"Human Papillomavirus (HPV) Prevalence in Male Adolescents 4 Years After HPV-16\/18 Vaccination","volume":"216","author":"Lehtinen","year":"2017","journal-title":"J Infect Dis"},{"key":"B100","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00705-009-0579-2","article-title":"Lack of heterogeneity of HPV16 E7 sequence compared with HPV31 and HPV73 may be related to its unique carcinogenic properties","volume":"155","author":"Safaeian","year":"2010","journal-title":"Arch Virol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"iv72","DOI":"10.1093\/annonc\/mdx220","article-title":"Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Marth","year":"2017","journal-title":"Ann Oncol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/ijc.30623","article-title":"Patterns of persistent HPV infection after treatment for cervical intraepithelial neoplasia (CIN): a systematic review","volume":"141","author":"Hoffman","year":"2017","journal-title":"Int J Cancer"},{"key":"B103","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3389\/fimmu.2019.00008","article-title":"Vaccine strategies to improve anti-cancer cellular immune responses","volume":"10","author":"Vermaelen","year":"2019","journal-title":"Front Immunol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.pvr.2017.12.006","article-title":"Therapeutic vaccines for high-risk HPV-associated diseases","volume":"5","author":"Chabeda","year":"2018","journal-title":"Papillomavirus Res"},{"key":"B105","doi-asserted-by":"publisher","first-page":"5086","DOI":"10.1073\/pnas.90.11.5086","article-title":"The E1 protein of bovine papilloma virus 1 is an ATP-dependent DNA helicase","volume":"90","author":"Yang","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"B106","doi-asserted-by":"publisher","first-page":"E48","DOI":"10.3390\/vaccines6030048","article-title":"Listeria monocytogenes as a vector for cancer immunotherapy: current understanding and progress","volume":"6","author":"Flickinger","year":"2018","journal-title":"Vaccines"},{"key":"B107","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1016\/j.vaccine.2009.04.041","article-title":"The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix","volume":"27","author":"Maciag","year":"2009","journal-title":"Vaccine"},{"key":"B108","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1093\/cid\/cir334","article-title":"Clinical applications of DNA vaccines: current progress","volume":"53","author":"Ferraro","year":"2011","journal-title":"Clin Infect Dis"},{"key":"B109","doi-asserted-by":"publisher","first-page":"5317","DOI":"10.1038\/ncomms6317","article-title":"Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients","volume":"5","author":"Kim","year":"2014","journal-title":"Nat Commun"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1007\/s00262-017-2006-y","article-title":"HPV16 E7 DNA tattooing: safety, immunogenicity, and clinical response in patients with HPV-positive vulvar intraepithelial neoplasia","volume":"66","author":"Samuels","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"B111","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1158\/1078-0432.CCR-08-1725","article-title":"A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2\/3","volume":"15","author":"Trimble","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B112","doi-asserted-by":"publisher","first-page":"155ra138","DOI":"10.1126\/scitranslmed.3004414","article-title":"Immunotherapy against HPV16\/18 generates potent TH1 and cytotoxic cellular immune responses","volume":"4","author":"Bagarazzi","year":"2012","journal-title":"Sci Transl Med"},{"key":"B113","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1089\/hum.2014.024","article-title":"Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine","volume":"25","author":"Rosales","year":"2014","journal-title":"Hum Gene Ther"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.4049\/jimmunol.1800219","article-title":"A prime-pull-amplify vaccination strategy to maximize induction of circulating and genital-resident intraepithelial CD8+ memory T cells","volume":"202","author":"\u00c7uburu","year":"2019","journal-title":"J Immunol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S1470-2045(17)30700-3","article-title":"Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis","volume":"18","author":"Arbyn","year":"2017","journal-title":"Lancet Oncol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/S1470-2045(07)70283-8","article-title":"Incomplete excision of cervical intraepithelial neoplasia and risk of treatment failure: a meta-analysis","volume":"8","author":"Ghaem-Maghami","year":"2007","journal-title":"Lancet Oncol"},{"key":"B118","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/j.1471-0528.2010.02770.x","article-title":"Determinants of success in treating cervical intraepithelial neoplasia","volume":"118","author":"Ghaem-Maghami","year":"2011","journal-title":"BJOG"},{"key":"B119","doi-asserted-by":"publisher","first-page":"a1284","DOI":"10.1136\/bmj.a1284","article-title":"Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis","volume":"18","author":"Arbyn","year":"2008","journal-title":"BMJ."},{"key":"B120","doi-asserted-by":"publisher","first-page":"i3633","DOI":"10.1097\/01.ogx.0000508341.95858.c5","article-title":"Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis","volume":"28","author":"Kyrgiou","year":"2016","journal-title":"BMJ."},{"key":"B121","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12985-019-1252-3","article-title":"HPV16 persistent infection and recurrent disease after LEEP","volume":"16","author":"Bruno","year":"2019","journal-title":"Virol J"},{"key":"B122","doi-asserted-by":"publisher","first-page":"f7361","DOI":"10.1136\/bmj.f7361","article-title":"Effect of ageing on cervical or vaginal cancer in Swedish women previously treated for cervical intraepithelial neoplasia grade 3: population based cohort study of long term incidence and mortality","volume":"348","author":"Strander","year":"2014","journal-title":"BMJ"},{"key":"B123","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1200\/JCO.2016.71.4543","article-title":"Long-lasting increased risk of human papillomavirus-related carcinomas and premalignancies after cervical intraepithelial neoplasia grade 3: a population-based cohort study","volume":"35","author":"Ebisch","year":"2017","journal-title":"J Clin Oncol"},{"key":"B124","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1093\/cid\/cir1036","article-title":"Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study","volume":"54","author":"Swedish","year":"2012","journal-title":"Clin Infect Dis"},{"key":"B125","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.ygyno.2013.04.050","article-title":"Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)?","volume":"130","author":"Kang","year":"2013","journal-title":"Gynecol Oncol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ygyno.2018.08.033","article-title":"SPERANZA project: HPV vaccination after treatment for CIN2","volume":"151","author":"Ghelardi","year":"2018","journal-title":"Gynecol Oncol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"212.e1","DOI":"10.1016\/j.ajog.2016.02.021","article-title":"Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment","volume":"215","author":"Hildesheim","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"e93393","DOI":"10.1371\/journal.pone.0093393","article-title":"Prevention of anal condyloma with quadrivalent human papillomavirus vaccination of older men who have sex with men","volume":"9","author":"Swedish","year":"2014","journal-title":"PLoS ONE"},{"key":"B129","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1001\/archdermatol.2010.290","article-title":"Regression of cutaneous warts in a patient with WILD syndrome following recombinant quadrivalent human papillomavirus vaccination","volume":"146","author":"Kreuter","year":"2010","journal-title":"Arch Dermatol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1111\/jdv.13133","article-title":"Dual response to human papilloma virus vaccine in an immunodeficiency disorder: resolution of plantar warts and persistence of condylomas","volume":"30","author":"Moscato","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B131","doi-asserted-by":"publisher","first-page":"e130","DOI":"10.1016\/j.jaad.2010.12.032","article-title":"Condyloma accuminatum treated with recombinant quadrivalent human papillomavirus vaccine (types 6, 11, 16, 18)","volume":"64","author":"Lee","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1080\/21645515.2018.1450125","article-title":"Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine","volume":"14","author":"Petry","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"B133","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.pvr.2017.02.003","article-title":"Vaccine-preventable anal human papillomavirus in Australian gay and bisexual men","volume":"3","author":"Poynten","year":"2017","journal-title":"Papillomavirus Res"},{"key":"B134","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/OLQ.0000000000000958","article-title":"Incidence, clearance, and persistence of anal human papillomavirus in men who have sex with men living with human immunodeficiency virus: implications for human papillomavirus vaccination","volume":"46","author":"Ong","year":"2019","journal-title":"Sex Transm Dis"},{"key":"B135","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/1471-0528.13071","article-title":"HPV-negative carcinoma of the uterine cervix: a distinct type of cervical cancer with poor prognosis","volume":"122","author":"Rodr\u00edguez-Carunchio","year":"2015","journal-title":"BJOG"},{"key":"B136","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/ajcp\/aqx027","article-title":"Polymerase chain reaction human papillomavirus (HPV) detection and HPV genotyping in Invasive cervical cancers with prior negative HC2 test results","volume":"147","author":"Tao","year":"2017","journal-title":"Am J Clin Pathol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.pvr.2017.10.003","article-title":"Surgical staging identified false HPV-negative cases in a large series of invasive cervical cancers","volume":"4","author":"Petry","year":"2017","journal-title":"Papillomavirus Res"},{"key":"B138","first-page":"107","article-title":"HPV negative cervical cancers and primary HPV screening","volume":"10","author":"Tjalma","year":"2018","journal-title":"Facts Views Vis Obgyn"},{"key":"B139","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1038\/modpathol.2014.55","article-title":"HPV prevalence and genotypes in different histological subtypes of cervical adenocarcinoma, a worldwide analysis of 760 cases","volume":"27","author":"Pirog","year":"2014","journal-title":"Mod Pathol"},{"key":"B140","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.5858\/arpa.2016-0356-RA","article-title":"Cervical adenocarcinoma: diagnosis of human papillomavirus-positive and human papillomavirus-negative tumors","volume":"141","author":"Pirog","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"B141","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.2353\/ajpath.2010.100323","article-title":"Absence of high-risk human papillomavirus (HPV) detection in endocervical adenocarcinoma with gastric morphology and phenotype","volume":"177","author":"Kusanagi","year":"2010","journal-title":"Am J Pathol"},{"key":"B142","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1097\/PAS.0b013e31821534b9","article-title":"Unusual endocervical adenocarcinomas: an immunohistochemical analysis with molecular detection of human papillomavirus","volume":"35","author":"Park","year":"2011","journal-title":"Am J Surg Pathol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00188\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T04:54:48Z","timestamp":1582001688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00188\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,18]]},"references-count":142,"alternative-id":["10.3389\/fimmu.2020.00188"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.00188","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,18]]},"article-number":"188"}}